Opportunities to improve clinical trial design in urothelial bladder cancer

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010;60:277–300
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research (CDER) -- Guidance for Industry. Code of Federal regulations Title 21: Section 314.510; Part 601.41 - Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidy. Available online at: http://wwwfdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501pdf, accessed 30 Nov 2012
   Google Scholar
• Johnson JR, Ning YM, Farrell A, et al. Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst 2011;103:636–44
   PubMedGoogle Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164–72
   PubMed Web of Science ®Google Scholar
• Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol Off J Am Soc Clin Oncol 2002;20:1304–10
   PubMed Web of Science ®Google Scholar
• Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 1999;17:460–9
   PubMed Web of Science ®Google Scholar
• Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol Off J Am Soc Clin Oncol 1995;13:1404–8
   PubMed Web of Science ®Google Scholar
• Hudson MA, Ratliff TL, Gillen DP, et al. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987;138:295–8
   PubMed Web of Science ®Google Scholar
• Badalament RA, Herr HW, Wong GY, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol Off J Am Soc Clin Oncol 1987;5:441–9
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124–9
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186–90, quiz 435
   PubMed Web of Science ®Google Scholar
• Berrum-Svennung I, Granfors T, Jahnson S, et al. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 2008;179:101–5; discussion 5–6
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86–91; discussion –92
   PubMed Web of Science ®Google Scholar
• Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90–5
   PubMed Web of Science ®Google Scholar
• Gontero P, Bohle A, Malmstrom PU, et al. The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010;57:410–29
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003;170:777–82
   PubMed Web of Science ®Google Scholar
• Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108–12
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Lurkin I, Radvanyi F, et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265–8
   PubMed Web of Science ®Google Scholar
• Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007;25:581–93
   PubMed Web of Science ®Google Scholar
• Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2001;54:215–21
   PubMedGoogle Scholar
• Santos LL, Pereira MK, Costa CS, et al. The prognostic value of MDM2 overexpression in superficial urothelial bladder carcinoma. Clin Transl Oncol 2002;4:322–6
   Google Scholar
• Lianes P, Orlow I, Zhang ZF, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994;86:1325–30
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005;48:189–99; discussion 99–201
   PubMed Web of Science ®Google Scholar
• Park J, Park S, Song C, et al. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy. Urology 2007;70:257–62
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Skoneczna I, Kerst JM, et al. Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. J Clin Oncol Off J Am Soc Clin Oncol 2014;32(Suppl 5):abstr 4500
   Google Scholar
• Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2005;2:CD005246
   PubMedGoogle Scholar
• Dash A, Pettus JAt, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008;113:2471–7
   PubMed Web of Science ®Google Scholar
• Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011;117:276–82
   PubMed Web of Science ®Google Scholar
• Cowan NG, Chen Y, Downs TM, et al. Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Adv Urol 2014;2014:746298
   PubMedGoogle Scholar
• Meeks JJ, Taylor JM, Matsushita K, et al. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int. 2013;111:E325–30
   PubMed Web of Science ®Google Scholar
• Petrelli F, Coinu A, Cabiddu M, et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 2014;65:350–7
   PubMed Web of Science ®Google Scholar
• Grivas PD, Hussain M, Hafez K, et al. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. Urology 2013;82:111–17
   PubMed Web of Science ®Google Scholar
• Zoidakis J, Makridakis M, Zerefos PG, et al. Profilin 1 is a potential biomarker for bladder cancer aggressiveness. Mol Cell Proteomics 2012;11(4):M111.009449-1-15
   Web of Science ®Google Scholar
• Costa VL, Henrique R, Danielsen SA, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res Off J Am Assoc Cancer Res 2010;16:5842–51
   PubMed Web of Science ®Google Scholar
• Kramer MW, Escudero DO, Lokeshwar SD, et al. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 2011;117:1197–209
   PubMed Web of Science ®Google Scholar
• Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62–7; discussion 7–8
   PubMed Web of Science ®Google Scholar
• James ND, Hussain SA, Hall H, et al. Results of a phase III randomized trial of synchronous chemoradiotherapy compared to radiotherapy alone in muscle-invasive bladder cancer. J Clin Oncol Off J Am Soc Clin Oncol 2010;28(Suppl 15):abstr 4517
   Google Scholar
• NCT00055835. S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine followed by Cisplatin and radiation therapy in treating patients with locally advanced or recurrent carcinoma of the urothelium. Available online at: https://clinicaltrialsgov/ct2/show/NCT00055835, accessed 27 Apr 2015
   Google Scholar
• James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477–88
   PubMed Web of Science ®Google Scholar
• Moynihan C, Hall E, Lewis R, et al. SPARE: a qualitative study investigating randomization barriers in a Selective Bladder Preservation trial (SBP) (ISCRCTN: 61126465). J Clin Oncol Off J Am Soc Clin Oncol 2009;27:(Suppl 15):abstr 5077
   Google Scholar
• von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol Off J Am Soc Clin Oncol 2005;23:4602–8
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol Off J Am Soc Clin Oncol 1999;17:3173–81
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol Off J Am Soc Clin Oncol 2009;27:4454–61
   PubMed Web of Science ®Google Scholar
• Papamichael D, Gallagher CJ, Oliver RT, et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997;75:606–7
   PubMed Web of Science ®Google Scholar
• NCT02033993. Trial comparing Nab-Paclitaxel to Paclitaxel in patients with advanced urothelial cancer progressing on or after platinum containing Regimen. Available online at: https://clinicaltrialsgov/ct2/show/NCT02033993, accessed 27 Apr 2015
   Google Scholar
• Sonpavde G, Pond GR, Fougeray R, et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 2013;63:717–23
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315–22
   PubMed Web of Science ®Google Scholar
• Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009;28:305–16
   PubMed Web of Science ®Google Scholar
• Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest J Tech Meth Pathol 2010;90:1406–14
   PubMed Web of Science ®Google Scholar
• Bambury RM, Rosenberg JE. Actionable mutations in muscle-invasive bladder cancer. Curr opin Urol 2013;23:472–8
   PubMed Web of Science ®Google Scholar
• Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol Off J Am Soc Clin Oncol 2007;25:2218–24
   PubMed Web of Science ®Google Scholar
• Oudard S, Culine S, Vieillefond A, et al. Multicenter randomized phase 2 trial of gemcitabine - pltinum with our without trastuzumab in advanced / metastatic urothelial carcinoma with HER2 overexpression. ESMO 2012(abstr 1111)
   Google Scholar
• Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997;80:1966–72
   PubMed Web of Science ®Google Scholar
• Petrioli R, Frediani B, Manganelli A, et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996;77:344–51
   PubMed Web of Science ®Google Scholar
• Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007;52:134–41
   PubMed Web of Science ®Google Scholar
• Seront E, Rottey S, Sautois B, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol Off J Eur Soc Med Oncol 2012;23:2663–70
   PubMed Web of Science ®Google Scholar
• Lyer G, Milowsky MI, Al-Ahmadie H, et al. Defining the genetic basis of everolimus sensitivity in metastatic bladder cancer by whole-genome sequencing. J Clin Oncol Off J Am Soc Clin Oncol 2012;30(Suppl):abstr 4527
   Google Scholar
• Powles T, Vogelzang NJ, Fine GD, et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in patients with metastatic urothelial bladder cancer J Clin Oncol Off J Am Soc Clin Oncol 2014;32(Suppl 5):abstr 5011
   Google Scholar
• NCT02108652. A study of MPDL3280A in patients with locally advanced or metastatic urothelial bladder cancer. Available online at: https://clinicaltrialsgov/ct2/show/NCT02108652, accessed 27 Apr 2015
   Google Scholar
• NCT01928394. A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in subjects with advanced or metastatic solid tumors. Available online at: https://clinicaltrialsgov/ct2/show/NCT01928394, accessed 27 Apr 2015
   Google Scholar
• Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006;107:506–13
   PubMed Web of Science ®Google Scholar
• von der Maase H, Andersen L, Crino L, et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol Off J Eur Soc Med Oncol 1999;10:1461–5
   PubMed Web of Science ®Google Scholar
• De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II–results of EORTC study 30986. J Clin Oncol Off J Am Soc Clin Oncol 2009;27:5634–9
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol 1997;15:2403–13
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76
   PubMed Web of Science ®Google Scholar
• de Haes J, Curran D, Young T, et al. Quality of life evaluation in oncological clinical trials - the EORTC model. The EORTC Quality of Life Study Group. Eur J Cancer 2000;36:821–5
   PubMed Web of Science ®Google Scholar
• Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337–43
   PubMed Web of Science ®Google Scholar
• Wright JL, Porter MP. Quality-of-life assessment in patients with bladder cancer. Nat Clin Pract Urol 2007;4:147–54
   PubMedGoogle Scholar
• Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459–64; discussion 64–7
   PubMed Web of Science ®Google Scholar
• Lehmann J, Franzaring L, Thuroff J, et al. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int 2006;97:42–7
   PubMed Web of Science ®Google Scholar
• Ruggeri EM, Giannarelli D, Bria E, et al. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer 2006;106:783–8
   PubMed Web of Science ®Google Scholar
• NCT01182168. Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in patients with advanced solid tumor malignancies. Available online at: https://clinicaltrialsgov/ct2/show/NCT01182168, accessed 27 Apr 2015
   Google Scholar
• NCT01215136. First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible patients with advanced urothelial carcinoma. Available online at: https://clinicaltrialsgov/ct2/show/NCT01215136, accessed 27 Apr 2015
   Google Scholar
• NCT01827943. Phase II evaluating efficacy of temsirolimus in 2 line therapy for patients with advanced bladder cancer. Available online at: https://clinicaltrialsgov/ct2/show/NCT01827943, accessed 27 Apr 2015
   Google Scholar
• NCT01551030. Buparlisib in metastatic transitional cell carcinoma of the urothelium. Available online at: https://clinicaltrialsgov/ct2/show/NCT01551030, accessed 27 Apr 2015
   Google Scholar
• NCT00942331. Gemcitabine hydrochloride and cisplatin with or without bevacizumab in treating patients with advanced urinary tract cancer. Available online at: https://clinicaltrialsgov/ct2/show/NCT00942331, accessed 27 Apr 2015
   Google Scholar
• NCT01844947. Phase I Study with sorafenib in addition to vinflunine in metastatic transitional cell carcinoma of the urothelial tract (VINSOR). Available online at: https://clinicaltrialsgov/ct2/show/NCT01844947, accessed 27 Apr 2015
   Google Scholar
• NCT01916109. Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. Available online at: https://clinicaltrialsgov/ct2/show/NCT01916109, accessed 27 Apr 2015
   Google Scholar
• NCT01191892. Carboplatin and gemcitabine hydrochloride with or without vandetanib as first-line therapy in treating patients with locally advanced or metastatic urinary tract cancer. Available online at: https://clinicaltrialsgov/ct2/show/NCT01191892, accessed 27 Apr 2015
   Google Scholar
• NCT01938573. Sirolimus, cisplatin, and gemcitabine hydrochloride in treating patients with bladder cancer. Available online at: https://clinicaltrialsgov/ct2/show/NCT01938573, accessed 27 Apr 2015
   Google Scholar
• NCT01375842. A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in patients with locally advanced or metastatic solid tumors. Available online at: https://clinicaltrialsgov/ct2/show/NCT01375842, accessed 27 Apr 2015
   Google Scholar
• NCT01522820. Vaccine therapy with or without sirolimus in treating patients with NY-ESO-1 expressing solid tumors. Available online at: https://clinicaltrialsgov/ct2/show/NCT01522820, accessed 27 Apr 2015
   Google Scholar
• NCT01326871. A Study of ALT-801 in combination with cisplatin and gemcitabine in muscle invasive or metastatic urothelial cancer. Available online at: https://wwwclinicaltrialsgov/ct2/show/NCT01326871, accessed 27 Apr 2015
   Google Scholar